文献速递儿童呼吸

优化儿童静脉沙丁胺醇用药:一项2期研究

Optimising intravenous salbutamol in children: a phase 2 study.
PubMed 文献 · Arch Dis Child · 2022-12-29

模型显示,推注后以0.5 µg/kg/min(最大20 µg/min)输注4小时可在12小时内达到>90%最大支气管扩张效应;更高输注速率与更明显的心动过速和高血糖相关。

要点

  • 推注后0.5 µg/kg/min(最大20 µg/min)输注4小时可获>90%最大支气管扩张效应并维持12小时
  • 更高输注速率与更明显心动过速和高血糖相关
  • 儿童沙丁胺醇PKPD模型可指导静脉给药方案优化

核心结论

  • 儿童静脉沙丁胺醇PKPD模型可描述浓度-效应关系,推注后0.5 µg/kg/min输注可实现有效支气管扩张。
  • 更高输注速率与更明显心动过速和高血糖相关。

研究设计与样本

  • 患儿来自两家伦敦医院急诊科或经儿童急性转运服务转入三家伦敦儿科重症监护病房。
  • 采用非线性混合效应模型进行PKPD建模。

主要发现

  • 二室PK模型可充分描述沙丁胺醇血药浓度时间过程。
  • EMAX浓度-效应关系可描述PASS和毒性指标。
  • PKPD模拟显示推注后0.5 µg/kg/min(最大20 µg/min)输注4小时可在12小时内达到>90%最大支气管扩张效应。
  • 更高输注速率与更明显心动过速和高血糖相关。

关键数值与推荐

  • 推注后0.5 µg/kg/min(最大20 µg/min)输注4小时,12小时内达到>90%最大支气管扩张效应。
  • 中位(范围)年龄2.9(1.1-15.2)岁,体重13.6(8-57.3)kg。

临床怎么用

  • 儿童急性哮喘静脉沙丁胺醇可参考推注后0.5 µg/kg/min(最大20 µg/min)输注4小时的方案。
  • 输注速率高于该方案时需关注心动过速和高血糖等不良反应。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The β2-agonists such as salbutamol are the mainstay of asthma management. Pharmacokinetic-pharmacodynamic (PKPD) models to guide paediatric dosing are lacking. We explored the relationship between salbutamol dose, serum concentration, effectiveness and adverse effects in children by developing a PKPD model. DESIGN: A prospective cohort study of children admitted to hospital with acute asthma, who received intravenous salbutamol. SETTING: Children were recruited in two cohorts: the emergency departments of two London hospitals or those retrieved by the Children's Acute Transport Service to three London paediatric intensive care units. PATIENTS: Patients were eligible if aged 1-15 years, admitted for acute asthma and about to receive or receiving intravenous salbutamol. INTERVENTIONS: Treatment was according to local policy. Serial salbutamol plasma levels were taken. Effectiveness measurements were recorded using the Paediatric Asthma Severity Score (PASS). Toxicity measurements included lactate, pH, glucose, heart rate, blood pressure and arrhythmias. PKPD modelling was performed with non-linear mixed-effect models. MAIN OUTCOMES: Fifty-eight children were recruited with 221 salbutamol concentration measurements from 54 children. Median (range) age was 2.9 (1.1-15.2) years, and weight was 13.6 (8-57.3) kg. Ninety-five PASS measurements and 2078 toxicity measurements were obtained. RESULTS: A two-compartment PK model adequately described the time course of salbutamol-plasma concentrations. An EMAX (maximum drug effect) concentration-effect relationship described PASS and toxicity measures. PKPD simulations showed an infusion of 0.5 µg/kg/min (maximum 20 µg/min) for 4 hours after bolus achieves >90% maximal bronchodilation for 12 hours. CONCLUSIONS: A paediatric PKPD model for salbutamol is described. An infusion of 0.5 µg/kg/min after bolus achieves effective bronchodilation. Higher rates are associated with greater tachycardia and hyperglycaemia.

来源:Arch Dis Child,查看原文。版权归原作者所有。

引用

  1. Walsh S, Pan S, Sheng Y, et al. Optimising intravenous salbutamol in children: a phase 2 study. Arch Dis Child. 2022. PMID: 36581395. doi:10.1136/archdischild-2022-324008

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。